Comparison · NCT01160640-sae
Ceftriaxone, Doxycycline, Metronidazole vs Ceftriaxone, Doxycycline, Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftriaxone, Doxycycline, Metronidazole vs Ceftriaxone, Doxycycline, Placebo: serious adverse events. Trial comparisons, record NCT01160640-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01160640-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0603 | 0.0295 | 0.119 | wilson | |
| Risk in group 2 | 0.0427 | 0.0184 | 0.0962 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0176 | -0.0441 | 0.0814 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.41 | 0.461 | 4.32 | log | |
| Odds ratio, group 1 over group 2 | 1.44 | 0.443 | 4.67 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ceftriaxone, Doxycycline, Metronidazole than on Ceftriaxone, Doxycycline, Placebo | 56.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftriaxone, Doxycycline, Metronidazole | ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days~ceftriaxone, doxycycline, metronidazole: ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days | 7 | 116 | EG001 |
| Group 2 | Ceftriaxone, Doxycycline, Placebo | ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo PO bid x 14 days~ceftriaxone, doxycycline, placebo: ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo PO bid x 14 days | 5 | 117 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 2 months
Source ClinicalTrials.gov
Trial
- Title
- The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
- NCT number
- NCT01160640
- Phases
- PHASE2
- Conditions
- Pelvic Inflammatory Disease
- Interventions
- Ceftriaxone, Doxycycline, Metronidazole, Placebo Oral Capsule
- Lead sponsor
- Harold Wiesenfeld
- Results first posted
- 2016-12-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01160640?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01160640-sae